Bastos, Diogo A; Mattedi, Romulo L; Barreiro, Rodrigo; Santos, Filipe F. dos; Buzatto, Vanessa; Masotti, Cibele; Souza, Jussara M; Nahas, Willian Carlos 
; Mello, Evandro Sobroza de; Chammas, Roger
Fonte: Bladder cancer. Unidade: FM
Assuntos: BIOMASSA, IMUNOTERAPIA, RISCO, SOBREVIDA, GENES, DANO AO DNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BASTOS, Diogo A et al. Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer. Bladder cancer, v. 6, n. 2, p. 171-186, 2020Tradução . . Disponível em: https://doi.org/10.3233/BLC-200289. Acesso em: 05 set. 2024.APA
Bastos, D. A., Mattedi, R. L., Barreiro, R., Santos, F. F. dos, Buzatto, V., Masotti, C., et al. (2020). Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer. Bladder cancer, 6( 2), 171-186. doi:10.3233/BLC-200289NLM
Bastos DA, Mattedi RL, Barreiro R, Santos FF dos, Buzatto V, Masotti C, Souza JM, Nahas WC, Mello ES de, Chammas R. Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer [Internet]. Bladder cancer. 2020 ; 6( 2): 171-186.[citado 2024 set. 05 ] Available from: https://doi.org/10.3233/BLC-200289Vancouver
Bastos DA, Mattedi RL, Barreiro R, Santos FF dos, Buzatto V, Masotti C, Souza JM, Nahas WC, Mello ES de, Chammas R. Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer [Internet]. Bladder cancer. 2020 ; 6( 2): 171-186.[citado 2024 set. 05 ] Available from: https://doi.org/10.3233/BLC-200289
